Georg Petzold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Georg Petzold has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Jan-Michael Peters
Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Campus-Vienna-Biocenter, 1030 Vienna, Austria
8 shared publications - Holger Stark
Department of Structural Dynamics, MPI for Biophysical Chemistry, Göttingen, Germany
7 shared publications - Brenda A. Schulman
Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
6 shared publications - Nicholas Gene Brown
Department of Pharmacology, University of North Carolina, Chapel Hill, USA
5 shared publications - Richard D. Bunker
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland
4 shared publications Bradley DeMarco
Monte Rosa Therapeutics, Inc., Boston, USA
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 20 January 2026
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 33 (3) , 479-487
Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry
Molecular glue degraders (MGDs) are small-molecule compounds that divert E3 ligases to degrade nonnatural substrates called neosubstrates. Clinically effective MGDs bind cereblon (CRBN), a substrate receptor of the Cullin 4–RING E3 ubiquitin ligase (CRL4CRBN), and recruit neosubstrates to an MGD-induced neosurface on the CRBN CULT domain through molecular mimicry of a natural CRBN degron. Here, we identify G3BP2 (Ras–GAP SH3 domain-binding protein 2), a neosubstrate that bypasses canonical interactions with CRBN by engaging an unconventional binding site on the CRBN LON domain. The ternary complex interface does not resemble known interactions with CRBN. Instead, CRBN leverages a preexisting protein–protein interaction (PPI) hotspot on the target protein by mimicking an endogenous binding partner of G3BP2. Our findings suggest that composite neosurfaces that mimic and stabilize the footprint of natural PPIs (in short, ‘glueprints’) could become a viable strategy for the rational expansion of the MGD target repertoire.
- 20 January 2026
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 33 (3) , 479-487
Top Cited PapersOpen AccessCereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry
Molecular glue degraders (MGDs) are small-molecule compounds that divert E3 ligases to degrade nonnatural substrates called neosubstrates. Clinically effective MGDs bind cereblon (CRBN), a substrate receptor of the Cullin 4–RING E3 ubiquitin ligase (CRL4CRBN), and recruit neosubstrates to an MGD-induced neosurface on the CRBN CULT domain through molecular mimicry of a natural CRBN degron. Here, we identify G3BP2 (Ras–GAP SH3 domain-binding protein 2), a neosubstrate that bypasses canonical interactions with CRBN by engaging an unconventional binding site on the CRBN LON domain. The ternary complex interface does not resemble known interactions with CRBN. Instead, CRBN leverages a preexisting protein–protein interaction (PPI) hotspot on the target protein by mimicking an endogenous binding partner of G3BP2. Our findings suggest that composite neosurfaces that mimic and stabilize the footprint of natural PPIs (in short, ‘glueprints’) could become a viable strategy for the rational expansion of the MGD target repertoire.
- Top Cited Papers
- 3 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6755) , eadt6736
Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
The CRL4 CRBN E3 ubiquitin ligase is the target of molecular glue degrader compounds that reprogram ligase specificity to induce the degradation of clinically relevant neosubstrate proteins. Known cereblon (CRBN) neosubstrates share a generalizable β-hairpin G-loop recognition motif that allows for the systematic exploration of the CRBN target space. Computational mining approaches using structure- and surface-based matchmaking algorithms predict more than 1600 CRBN-compatible G-loop proteins across the human proteome, including the newly discovered helical G-loop motif, and identify the noncanonical neosubstrate binding mode of VAV1 that engages CRBN through a molecular surface mimicry mechanism. This work broadens the CRBN target space, redefines rules for neosubstrate recognition, and establishes a platform for the elimination of challenging drug targets by repurposing CRL4 CRBN through next-generation molecular glue degraders.
- 3 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6755) , eadt6736
Top Cited PapersMining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
The CRL4 CRBN E3 ubiquitin ligase is the target of molecular glue degrader compounds that reprogram ligase specificity to induce the degradation of clinically relevant neosubstrate proteins. Known cereblon (CRBN) neosubstrates share a generalizable β-hairpin G-loop recognition motif that allows for the systematic exploration of the CRBN target space. Computational mining approaches using structure- and surface-based matchmaking algorithms predict more than 1600 CRBN-compatible G-loop proteins across the human proteome, including the newly discovered helical G-loop motif, and identify the noncanonical neosubstrate binding mode of VAV1 that engages CRBN through a molecular surface mimicry mechanism. This work broadens the CRBN target space, redefines rules for neosubstrate recognition, and establishes a platform for the elimination of challenging drug targets by repurposing CRL4 CRBN through next-generation molecular glue degraders.
- Open Access
Molecular surface mimicry enables CRBN to target G3BP2 for degradation
Molecular glue degraders (MGDs) are small molecule compounds that repurpose the ubiquitin-proteasome system to induce degradation of challenging therapeutic targets. Clinically effective MGDs bind cereblon (CRBN), a substrate receptor of the Cullin-4/RING E3 ubiquitin ligase (CRL4CRBN), and impose a gain-of-function activity to recruit, ubiquitinate and degrade so-called neosubstrate proteins. Known neosubstrates bind the CRBN/MGD neosurface on the CRBN CULT domain through a structural G-loop recognition motif that mimics contacts of a natural CRBN degron. Here we report the binding mode of G3BP2, a CRBN neosubstrate that bypasses the G-loop requirement by engaging an unconventional binding site on the CRBN LON domain. The MGD-induced ternary complex interface does not resemble known protein-protein interactions (PPI) with CRBN. Instead, CRBN mimics an endogenous binding partner of G3BP2 and repurposes a preexisting PPI hotspot on the target protein. Our findings provide a novel generalizable concept for the rationalization of unconventional neosubstrate binding modes on CRBN, demonstrate unprecedented potential for the reprogrammability of this substrate receptor by MGDs, and offer opportunities for rational expansion of the target repertoire accessible to this modality.
Open AccessMolecular surface mimicry enables CRBN to target G3BP2 for degradation
Molecular glue degraders (MGDs) are small molecule compounds that repurpose the ubiquitin-proteasome system to induce degradation of challenging therapeutic targets. Clinically effective MGDs bind cereblon (CRBN), a substrate receptor of the Cullin-4/RING E3 ubiquitin ligase (CRL4CRBN), and impose a gain-of-function activity to recruit, ubiquitinate and degrade so-called neosubstrate proteins. Known neosubstrates bind the CRBN/MGD neosurface on the CRBN CULT domain through a structural G-loop recognition motif that mimics contacts of a natural CRBN degron. Here we report the binding mode of G3BP2, a CRBN neosubstrate that bypasses the G-loop requirement by engaging an unconventional binding site on the CRBN LON domain. The MGD-induced ternary complex interface does not resemble known protein-protein interactions (PPI) with CRBN. Instead, CRBN mimics an endogenous binding partner of G3BP2 and repurposes a preexisting PPI hotspot on the target protein. Our findings provide a novel generalizable concept for the rationalization of unconventional neosubstrate binding modes on CRBN, demonstrate unprecedented potential for the reprogrammability of this substrate receptor by MGDs, and offer opportunities for rational expansion of the target repertoire accessible to this modality.
- 1 January 2020
- Published by Elsevier in Cell Chemical Biology
- Vol. 27 (1) , 16-18
Taking the Brakes Off Targeted Protein Degradation
- 1 January 2020
- Published by Elsevier in Cell Chemical Biology
- Vol. 27 (1) , 16-18
Taking the Brakes Off Targeted Protein Degradation
- Top Cited Papers
- 2 November 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 362 (6414) , 558-+
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Thalidomide-targeted degradation: Thalidomide and its analogs improve the survival of patients with multiple myeloma and other blood cancers. Previous work showed that the drugs bind to the E3 ubiquitin ligase Cereblon, which then targets for degradation two specific zinc finger (ZF) transcription factors with a role in cancer development. Sievers et al. found that more ZF proteins than anticipated are destabilized by thalidomide analogs. A proof-of-concept experiment revealed that chemical modifications of thalidomide can lead to selective degradation of specific ZF proteins. The detailed information provided by structural, biochemical, and computational analyses could guide the development of drugs that target ZF transcription factors implicated in human disease. Science , this issue p. eaat0572
- 2 November 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 362 (6414) , 558-+
Top Cited PapersDefining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Thalidomide-targeted degradation: Thalidomide and its analogs improve the survival of patients with multiple myeloma and other blood cancers. Previous work showed that the drugs bind to the E3 ubiquitin ligase Cereblon, which then targets for degradation two specific zinc finger (ZF) transcription factors with a role in cancer development. Sievers et al. found that more ZF proteins than anticipated are destabilized by thalidomide analogs. A proof-of-concept experiment revealed that chemical modifications of thalidomide can lead to selective degradation of specific ZF proteins. The detailed information provided by structural, biochemical, and computational analyses could guide the development of drugs that target ZF transcription factors implicated in human disease. Science , this issue p. eaat0572
- 13 April 2017
- Published by Springer Nature in Nature Chemical Biology
- Vol. 13 (5) , 452-453
You can glue it too!
- 13 April 2017
- Published by Springer Nature in Nature Chemical Biology
- Vol. 13 (5) , 452-453
You can glue it too!
- Top Cited Papers
- 25 April 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (19) , E2564-E2569
biGBac enables rapid gene assembly for the expression of large multisubunit protein complexes
Significance: At the molecular level, most processes in living systems are mediated by multisubunit protein complexes. Recombinant forms of these complexes are essential for analyzing their structure and function. Multigene expression constructs greatly improve recombinant protein complex preparations, but the generation of such constructs can be a rate-limiting step. To overcome this limitation, we have adapted Gibson assembly reactions for the rapid, efficient, and fast generation of numerous expression constructs in parallel and used the resulting biGBac method for expression of different cell-cycle complexes, composed of up to 17 different subunits. The biGBac technique enables the analyses of large protein complexes by systematic mutagenesis approaches that were not feasible before.
- 25 April 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (19) , E2564-E2569
Top Cited PapersbiGBac enables rapid gene assembly for the expression of large multisubunit protein complexes
Significance: At the molecular level, most processes in living systems are mediated by multisubunit protein complexes. Recombinant forms of these complexes are essential for analyzing their structure and function. Multigene expression constructs greatly improve recombinant protein complex preparations, but the generation of such constructs can be a rate-limiting step. To overcome this limitation, we have adapted Gibson assembly reactions for the rapid, efficient, and fast generation of numerous expression constructs in parallel and used the resulting biGBac method for expression of different cell-cycle complexes, composed of up to 17 different subunits. The biGBac technique enables the analyses of large protein complexes by systematic mutagenesis approaches that were not feasible before.
- 30 March 2016
- Published by Springer Nature in Nature
- Vol. 531 (7596) , 598-603
Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome
The cullin–RING ubiquitin E3 ligase (CRL) family comprises over 200 members in humans. The COP9 signalosome complex (CSN) regulates CRLs by removing their ubiquitin-like activator NEDD8. The CUL4A–RBX1–DDB1–DDB2 complex (CRL4ADDB2) monitors the genome for ultraviolet-light-induced DNA damage. CRL4ADBB2 is inactive in the absence of damaged DNA and requires CSN to regulate the repair process. The structural basis of CSN binding to CRL4ADDB2 and the principles of CSN activation are poorly understood. Here we present cryo-electron microscopy structures for CSN in complex with neddylated CRL4A ligases to 6.4 Å resolution. The CSN conformers defined by cryo-electron microscopy and a novel apo-CSN crystal structure indicate an induced-fit mechanism that drives CSN activation by neddylated CRLs. We find that CSN and a substrate cannot bind simultaneously to CRL4A, favouring a deneddylated, inactive state for substrate-free CRL4 complexes. These architectural and regulatory principles appear conserved across CRL families, allowing global regulation by CSN.
- 30 March 2016
- Published by Springer Nature in Nature
- Vol. 531 (7596) , 598-603
Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome
The cullin–RING ubiquitin E3 ligase (CRL) family comprises over 200 members in humans. The COP9 signalosome complex (CSN) regulates CRLs by removing their ubiquitin-like activator NEDD8. The CUL4A–RBX1–DDB1–DDB2 complex (CRL4ADDB2) monitors the genome for ultraviolet-light-induced DNA damage. CRL4ADBB2 is inactive in the absence of damaged DNA and requires CSN to regulate the repair process. The structural basis of CSN binding to CRL4ADDB2 and the principles of CSN activation are poorly understood. Here we present cryo-electron microscopy structures for CSN in complex with neddylated CRL4A ligases to 6.4 Å resolution. The CSN conformers defined by cryo-electron microscopy and a novel apo-CSN crystal structure indicate an induced-fit mechanism that drives CSN activation by neddylated CRLs. We find that CSN and a substrate cannot bind simultaneously to CRL4A, favouring a deneddylated, inactive state for substrate-free CRL4 complexes. These architectural and regulatory principles appear conserved across CRL families, allowing global regulation by CSN.
- Top Cited Papers
- 24 February 2016
- Published by Springer Nature in Nature
- Vol. 532 (7597) , 127-130
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4–RBX1–DDB1–CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates. Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degradation. Lenalidomide induces degradation of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clinical efficacy in the treatment of multiple myeloma and 5q-deletion associated myelodysplastic syndrome (del(5q) MDS), respectively. How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive. Here we present the 2.45 Å crystal structure of DDB1–CRBN bound to lenalidomide and CK1α. CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe. We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD. Binding of IKZF1 to CRBN similarly requires the compound and both, IKZF1 and CK1α, use a related binding mode. Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy. We anticipate that high-affinity protein–protein interactions induced by small molecules will provide opportunities for drug development, particularly for targeted protein degradation.
- 24 February 2016
- Published by Springer Nature in Nature
- Vol. 532 (7597) , 127-130
Top Cited PapersStructural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4–RBX1–DDB1–CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates. Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degradation. Lenalidomide induces degradation of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clinical efficacy in the treatment of multiple myeloma and 5q-deletion associated myelodysplastic syndrome (del(5q) MDS), respectively. How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive. Here we present the 2.45 Å crystal structure of DDB1–CRBN bound to lenalidomide and CK1α. CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe. We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD. Binding of IKZF1 to CRBN similarly requires the compound and both, IKZF1 and CK1α, use a related binding mode. Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy. We anticipate that high-affinity protein–protein interactions induced by small molecules will provide opportunities for drug development, particularly for targeted protein degradation.